Emapalumab-lzsg 25 mg/ML [Gamifant]
RxNorm 2665327

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2665327 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: emapalumab-lzsg 25 mg/ML [Gamifant].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Emapalumab-lzsg 25 mg/ML [Gamifant]
AUI:12853257
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Emapalumab-lzsg 25 mg/ML [Gamifant]
(Atom ID: 12853257)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
emapalumab-lzsg 25 MG/ML [Gamifant]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2665327
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12853257
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2665327
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Emapalumab-lzsg Injection


Emapalumab-lzsg injection is used to treat adults and children (newborn and older) with primary hemophagocytic lymphohistiocytosis (HLH; an inherited condition in which the immune system does not work normally and causes swelling and damage to the liver, brain, and bone marrow) whose disease has not improved, has gotten worse, or has come back after previous treatment or who are unable to take other medications. Emapalumab-lzsg injection is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in the immune system that causes inflammation.
[Learn More]


* Please review the disclaimer below.